Robert J. Israel
About
In The Last Decade
Robert J. Israel
84 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 94
- Gastroenterology 448
- Surgery 421
- Molecular Biology 281
- Immunology 258
- Virology 241
Countries citing papers authored by Robert J. Israel
This map shows the geographic impact of Robert J. Israel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Israel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Israel more than expected).
Fields of papers citing papers by Robert J. Israel
This network shows the impact of papers produced by Robert J. Israel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Israel. The network helps show where Robert J. Israel may publish in the future.
Co-authorship network of co-authors of Robert J. Israel
This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Israel. A scholar is included among the top collaborators of Robert J. Israel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Israel. Robert J. Israel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 17 | |
| 4 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials | 1 |
| 5 | Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials. | 4 |
| 6 | Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies. | 12 |
| 7 | 7 | |
| 8 | 9 | |
| 9 | 10 | |
| 10 | 39 | |
| 11 | 54 | |
| 12 | 57 | |
| 13 | Correlation of Technetium Tc99m trofolastat chloride (MIP-1404) uptake using SPECT/CT with histopathology: A phase 2 study of prostate cancer (PCa) patients undergoing radical prostatectomy (RP) with extended lymph node dissection (ePLND) | 2 |
| 14 | 15 | |
| 15 | 4 | |
| 16 | 10 | |
| 17 | 23 | |
| 18 | 11 | |
| 19 | 115 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.